Literature DB >> 8872774

A clinicopathological study on combined hepatocellular and cholangiocarcinoma.

J Taguchi1, O Nakashima, M Tanaka, T Hisaka, T Takazawa, M Kojiro.   

Abstract

We clinicopathologically studied 23 surgically resected cases of combined hepatocellular and cholangiocarcinoma (HCC-CC). The frequency of this cancer in our subjects, who had primary liver cancer and who underwent hepatectomy, was 6.3%. The mean age of patients was 64.0 years old and the male: female ratio was 1.9:1. Serum alpha-fetoprotein was positive in 70% of cases and its levels were relatively low (< or = 1000 ng/mL) in most cases. The positive rate of serum carcinoembryonic antigen was 18% and its levels were also low. In regard to hepatitis virus markers, 17% of the 20 combined HCC-CC cases were positive to HBs antigen and 70% were positive to the HCV antibody. Of the 23 combined HCC-CC cases, 9 cases (39%) were associated with liver cirrhosis. Tumours were classified macroscopically into a separated type (HCC and CC are clearly separated 17%), a HCC-predominant type (resembles HCC 49%), and a CC-predominant type (resembles CC 34%). The separated and HCC-predominant types were associated with liver cirrhosis in 50 and 55% of cases, respectively. These cases with liver cirrhosis presented the features of HCC more apparently, while those without liver cirrhosis presented the features of CC. Histologically, all cases were classified into either Type I (HCC and CC were clearly distinguished; 17%), Type II (HCC and CC were contiguous and shared transitional features; 66%), and Type III (cancer cells were able to be evaluated as either HCC or CC and were considered to be an intermediate type; 17%). Immunohistological stains for cytokeratin were useful to distinguish HCC and CC. Specifically, CC was positive to cytokeratin 7 and 19. The tumour, in which HCC and CC were almost indistinguishable, such as Type III), indicates the presence of intermediate tumour cells that can differentiate either to HCC or CC.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8872774     DOI: 10.1111/j.1440-1746.1996.tb00327.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  34 in total

Review 1.  Biphenotypic (hepatobiliary) primary liver carcinomas: the work in progress.

Authors:  Elizabeth M Brunt; Valerie Paradis; Christine Sempoux; Neil D Theise
Journal:  Hepat Oncol       Date:  2015-07-28

Review 2.  Combined hepatocellular cholangiocarcinoma: a case report and review of literature.

Authors:  Shailender Singh; Subhankar Chakraborty; Neelima Bonthu; Stanley Radio; Shahid M Hussain; Aaron Sasson
Journal:  Dig Dis Sci       Date:  2013-02-09       Impact factor: 3.199

3.  Risk factors for combined hepatocellular-cholangiocarcinoma: a hospital-based case-control study.

Authors:  Yan-Ming Zhou; Xiao-Feng Zhang; Lu-Peng Wu; Cheng-Jun Sui; Jia-Mei Yang
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

4.  Expression of both hepatocellular carcinoma and cholangiocarcinoma phenotypes in hepatocellular carcinoma and cholangiocarcinoma components in combined hepatocellular and cholangiocarcinoma.

Authors:  Mitsumaro Itoyama; Masaki Hata; Koji Yamanegi; Naoko Yamada; Hideki Ohyama; Hiroshi Hirano; Nobuyuki Terada; Keiji Nakasho
Journal:  Med Mol Morphol       Date:  2012-03-20       Impact factor: 2.309

5.  Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma.

Authors:  Won-Suk Lee; Kwang-Woong Lee; Jin-Seok Heo; Sung-Ju Kim; Seong-Ho Choi; Yong-Il Kim; Jae-Won Joh
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

6.  Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with combined hepatocellular-cholangiocarcinoma.

Authors:  Chae Hong Lim; Seung Hwan Moon; Young Seok Cho; Joon Young Choi; Kyung-Han Lee; Seung Hyup Hyun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-05-02       Impact factor: 9.236

7.  Postresection Outcomes of Combined Hepatocellular Carcinoma-Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

Authors:  Young-In Yoon; Shin Hwang; Young-Joo Lee; Ki-Hun Kim; Chul-Soo Ahn; Deok-Bog Moon; Tae-Yong Ha; Gi-Won Song; Dong-Hwan Jung; Jong-Woo Lee; Seung-Mo Hong; Eun Sil Yu; Sung-Gyu Lee
Journal:  J Gastrointest Surg       Date:  2015-12-01       Impact factor: 3.452

8.  Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS database.

Authors:  Valery Vilchez; Malay B Shah; Michael F Daily; Luis Pena; Ching-Wei D Tzeng; Daniel Davenport; Peter J Hosein; Roberto Gedaly; Erin Maynard
Journal:  HPB (Oxford)       Date:  2016-01-07       Impact factor: 3.647

9.  Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer.

Authors:  T Uenishi; S Kubo; K Hirohashi; H Tanaka; T Shuto; T Yamamoto; S Nishiguchi
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

10.  Hepatocellular carcinoma with characteristic mucin production: a case report.

Authors:  Kyung Hwa Lee; Young Bog Kim; Sung Bum Cho; Min Cheol Lee; Chang Soo Park; Jae Hyuk Lee
Journal:  Cases J       Date:  2009-08-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.